102 related articles for article (PubMed ID: 7562399)
1. [Serum 1-methyladenosine and pseudouridine as tumor markers in tumor-bearing mice].
Ishiwata S; Itoh K; Yamaguchi T; Sasaki S; Ishida N; Mizugaki M
Yakugaku Zasshi; 1995 Jul; 115(7):523-7. PubMed ID: 7562399
[TBL] [Abstract][Full Text] [Related]
2. An immunohistochemical analysis for cancer of the esophagus using monoclonal antibodies specific for modified nucleosides.
Masuda M; Nishihira T; Itoh K; Mizugaki M; Ishida N; Mori S
Cancer; 1993 Dec; 72(12):3571-8. PubMed ID: 8252470
[TBL] [Abstract][Full Text] [Related]
3. [Molecular and immunological approach to hematological disease: detection and analysis of intracellular modified nucleosides by flow cytometry].
Hoshino A; Honda I; Ishimori A; Itoh K; Mizugaki M; Nose M
Rinsho Byori; 1990 Jul; 38(7):756-64. PubMed ID: 2402080
[TBL] [Abstract][Full Text] [Related]
4. Relationship of urinary pseudouridine and 1-methyladenosine to activity of leukemia and lymphoma.
Itoh K; Konno T; Sasaki T; Ishiwata S; Ishida N; Misugaki M
Clin Chim Acta; 1992 Mar; 206(3):181-9. PubMed ID: 1606704
[TBL] [Abstract][Full Text] [Related]
5. Creatinine at the evaluation of urinary 1-methyladenosine and pseudouridine excretion.
Honda I; Itoh K; Mizugaki M; Sasaki T
Tohoku J Exp Med; 1999 Jun; 188(2):133-8. PubMed ID: 10526874
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic use of anti-modified nucleoside monoclonal antibody.
Itoh K; Ishiwata S; Ishida N; Mizugaki M
Tohoku J Exp Med; 1992 Oct; 168(2):329-31. PubMed ID: 1306318
[TBL] [Abstract][Full Text] [Related]
7. Serum pseudouridine as a biochemical marker in the development of AKR mouse lymphoma.
Russo T; Colonna A; Salvatore F; Cimino F; Bridges S; Gurgo C
Cancer Res; 1984 Jun; 44(6):2567-70. PubMed ID: 6722793
[TBL] [Abstract][Full Text] [Related]
8. Serum pseudouridine as a biochemical marker in patients with hepatocellular carcinoma.
Amuro Y; Nakaoka H; Shimomura S; Fujikura M; Yamamoto T; Tamura S; Hada T; Higashino K
Clin Chim Acta; 1988 Dec; 178(2):151-8. PubMed ID: 2854011
[TBL] [Abstract][Full Text] [Related]
9. Quantitation of urinary nucleosides by high-performance liquid chromatography.
Liebich HM; Di Stefano C; Wixforth A; Schmid HR
J Chromatogr A; 1997 Feb; 763(1-2):193-7. PubMed ID: 9129323
[TBL] [Abstract][Full Text] [Related]
10. Determination of pseudouridine and other nucleosides in human blood serum by high-performance liquid chromatography.
Colonna A; Russo T; Esposito F; Salvatore F; Cimino F
Anal Biochem; 1983 Apr; 130(1):19-26. PubMed ID: 6869800
[TBL] [Abstract][Full Text] [Related]
11. Urinary excretion patterns of modified nucleosides, pseudouridine and 1-methyladenosine, in healthy individuals.
Itoh K; Aida S; Ishiwata S; Sasaki S; Ishida N; Mizugaki M
Clin Chim Acta; 1993 Aug; 217(2):221-3. PubMed ID: 8261632
[No Abstract] [Full Text] [Related]
12. [Determination of pseudouridine in serum by high performance liquid chromatography].
Hu Y; Tang Q; Liu B
Se Pu; 1997 Jul; 15(4):349-51. PubMed ID: 15739475
[TBL] [Abstract][Full Text] [Related]
13. Relationship between urinary excretion of modified nucleosides and rheumatoid arthritis process.
Tebib JG; Reynaud C; Cedoz JP; Letroublon MC; Niveleau A
Br J Rheumatol; 1997 Sep; 36(9):990-5. PubMed ID: 9376997
[TBL] [Abstract][Full Text] [Related]
14. Immuno-Northern Blotting: Detection of Modified RNA Using Gel Separation and Antibodies to Modified Nucleosides.
Mishima E; Abe T
Methods Mol Biol; 2019; 1870():179-187. PubMed ID: 30539555
[TBL] [Abstract][Full Text] [Related]
15. Urinary modified nucleosides as tumor markers in cancer of the urinary organs or female genital tract.
Koshida K; Harmenberg J; Stendahl U; Wahren B; Borgström E; Helström L; Andersson L
Urol Res; 1985; 13(5):213-8. PubMed ID: 4060364
[TBL] [Abstract][Full Text] [Related]
16. Low molecular weight immunosuppressive factors found in elevated amounts in cancer ascitic fluids of mice. 2. 1-Methyladenosine isolated from cancer ascitic fluids enhances Listeria infection in mice.
Takano S; Sami S; Majima T; Ishida N
J Immunopharmacol; 1986; 8(1):59-73. PubMed ID: 3711674
[TBL] [Abstract][Full Text] [Related]
17. Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA.
Ishiwata S; Itoh K; Yamaguchi T; Ishida N; Mizugaki M
Tohoku J Exp Med; 1995 May; 176(1):61-8. PubMed ID: 7482520
[TBL] [Abstract][Full Text] [Related]
18. Modified nucleosides: an accurate tumour marker for clinical diagnosis of cancer, early detection and therapy control.
Seidel A; Brunner S; Seidel P; Fritz GI; Herbarth O
Br J Cancer; 2006 Jun; 94(11):1726-33. PubMed ID: 16685264
[TBL] [Abstract][Full Text] [Related]
19. Pyrimidine nucleoside, pseudouridine, and modified nucleoside excretion by growing and resting fibroblasts.
Uziel M; Selkirk JK
J Cell Physiol; 1979 May; 99(2):217-22. PubMed ID: 457787
[TBL] [Abstract][Full Text] [Related]
20. Monitoring of urinary excretion of modified nucleosides in cancer patients using a set of six monoclonal antibodies.
Reynaud C; Bruno C; Boullanger P; Grange J; Barbesti S; Niveleau A
Cancer Lett; 1992 Jan; 61(3):255-62. PubMed ID: 1739950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
